US equities
|
SPCX
$166.94
▲+5.02%
NVDA
$237.11
▲+1.35%
MU
$1,066.80
▼-0.75%
TSLA
$375.58
▲+1.35%
MSFT
$526.27
▲+1.69%
INTC
$117.14
▼-1.84%
SNDK
$1,722.72
▲+0.16%
META
$743.49
▲+2.12%
SPCX
$166.94
▲+5.02%
NVDA
$237.11
▲+1.35%
MU
$1,066.80
▼-0.75%
TSLA
$375.58
▲+1.35%
MSFT
$526.27
▲+1.69%
INTC
$117.14
▼-1.84%
SNDK
$1,722.72
▲+0.16%
META
$743.49
▲+2.12%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
ObsEva SA - Common Shares
(NQ:
OBSV
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 22, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ObsEva SA - Common Shares
< Previous
1
2
3
4
5
6
Next >
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
↗
July 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI...
Via
Benzinga
34 Stocks Moving in Tuesday's Pre-Market Session
↗
July 27, 2021
Gainers Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) shares rose 139.7% to $7.48 in pre-market trading after the company announced it entered a non-binding letter of intent to...
Via
Benzinga
ObsEva Stock Surges On Potential $500M Ebopiprant Deal For Preterm Labor
↗
July 27, 2021
Organon & Co (NYSE: OGN) will license the global development, manufacturing, and commercial rights to ObsEva SA's (NASDAQ: OBSV) ebopiprant (OBE022)...
Via
Benzinga
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor
July 27, 2021
From
Organon
Via
Business Wire
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision And Conference Presentations In A Light Week
↗
July 03, 2021
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few COVID-19 disappointments,...
Via
Talk Markets
The Week Ahead In Biotech: Focus On Chemocentryx FDA Decision, Conference Presentations In A Light Week
↗
July 03, 2021
Biotech stocks advanced for a second week in running, with stocks reacting to pending releases for the second quarter and the first-half of the year. The week witnessed a few...
Via
Benzinga
The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal
↗
June 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9) Aethlon Medical, Inc. (...
Via
Benzinga
The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs
↗
June 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) 10x Genomics, Inc. (NASDAQ...
Via
Benzinga
38 Stocks Moving In Thursday's Mid-Day Session
↗
May 20, 2021
Gainers Newegg Commerce Inc. (NASDAQ: NEGG) shares jumped 30% to $12.03. Precipio, Inc. (NASDAQ: PRPO) gained 22.3% to $5.05. Precipio recently announced it launched a new, four-...
Via
Benzinga
OBSV Stock: The Big Clinical Trial News Boosting ObsEva Today
↗
May 20, 2021
OBSV stock is on the move Thursday after ObsEva shared promising updates on its trials for a uterine fibroid treatment.
Via
InvestorPlace
20 Stocks Moving in Thursday's Pre-Market Session
↗
May 20, 2021
Gainers PDS Biotechnology Corporation (NASDAQ: PDSB) rose 18% to $6.77 in pre-market trading as traders circulated abstract from American Society Of Clinical Oncology website....
Via
Benzinga
ObsEva Shares Gains On Positive Linzagolix Data In Uterine Fibroids Study
↗
May 20, 2021
ObsEva SA (NASDAQ: OBSV) has announced final 76-week results from the PRIMROSE 1 Phase 3 clinical study evaluating Yselty (linzagolix) for heavy menstrual bleeding...
Via
Benzinga
ObsEva Starts Long-term Follow-Up Study To Evaluate Bone Mineral Density After Yselty Treatment
↗
April 27, 2021
ObsEva SA (NASDAQ: OBSV) has initiated the observational PRIMROSE 3 study to evaluate long-term bone mineral density (BMD) in subjects who completed at least...
Via
Benzinga
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
↗
May 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout
↗
April 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 26) 10x Genomics, Inc. (NASDAQ...
Via
Benzinga
Topics
Intellectual Property
< Previous
1
2
3
4
5
6
Next >
